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Abstract
Objective: The prognostic value of anti-angiogenesis therapy in ovarian cancer patients is currently under debate.
In this study, we assessed the effects of anti-angiogenesis therapy on the progression free survival (PFS) and overall
survival (OS) of ovarian cancer patients.
Materials and methods: PubMed was searched to identify relevant studies that evaluated the therapeutic value of
anti-angiogenic agents in ovarian cancer (the final search was current to Dec. 13th 2014). Reviews of each study were
conducted, and the data were extracted. The primary outcomes that were analysed were progression free survival
(PFS) and overall survival (OS). The pooled hazard ratio (HR) and 95 % confidence intervals (CIs) were calculated using
the random and fixed-effects models, and subgroup and sensitivity analyses were subsequently performed.
Results: A total of 12 studies were included in the meta-analysis. The overall analysis revealed that the incorporation of
anti-angiogenesis therapy was significantly associated with a longer PFS (HR, 0.66; 95 % CI, 0.58-0.75; P < 0.01) and a
longer OS (HR, 0.89; 95 % CI, 0.82-0.97; P = 0.01) in the total population, and these findings were confirmed by one-way
sensitivity analyses. Further subgroup analyses demonstrated that the administrations of each of the agents were
associated with improved PFSs. The prognostic value of anti-angiogenesis therapy for the OS was significant in the
trebananib subgroup (HR, 0.81; 95 % CI, 0.67-0.99; P = 0.04). The bevacizumab subgroup exhibited a similar trend that did
not reach statistical significance (HR, 0.90; 95 % CI, 0.80-1.01; P = 0.08).
Conclusions: The present meta-analysis indicated that anti-angiogenesis therapy in ovarian cancer patients was
associated with a better clinical outcome. Further studies are warranted to identify the specific subgroup of patients who
are most likely to benefit from anti-angiogenesis therapy.
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Background
Worldwide, approximately 238,000 women are diagnosed
with ovarian cancer and 151,000 women succumb to this
disease in 2012. Currently, the standard treatment for ovar-
ian cancer is aggressive cytoreductive surgery, followed by a
platinum and taxane combination chemotherapy [1]. Al-
though 70 % of the patients will experience a complete clin-
ical remission after the initial therapy, the majority will
eventually experience a cancer progression and succumb to
their disease [2]. Thus, ovarian cancer patients usually
require further treatments. With the aim of improving the
prognoses of ovarian cancer patients, multiple clinical trials
have been conducted to explore new therapies, including
anti-angiogenesis therapy [3].
Angiogenesis is a complex, multi-step process that is
controlled by several key pathways, including the vascular
endothelial growth factor (VEGF) pathway, the platelet-
derived growth factor (PDGF) pathway, the fibroblast
growth factor (FGF) pathway, and the angiopoietin-Tie2
receptor pathway [4]. Accumulating evidence has demon-
strated that the disruption of the angiogenesis axis is
involved in the progression of ovarian cancer via the pro-
motion of tumor growth, ascites, and metastases [5]. Due
to these findings, anti-angiogenesis therapy has been
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extensively studied in patients with ovarian cancer
[6, 7]. Promisingly, extended progression free survival
(PFS) has been observed in patients who receive anti-
angiogenesis therapy. However, it is not appropriate to
simplify the clinical benefit of new drugs to improve-
ments in PFS, and overall survival (OS) is also a key
secondary study endpoint. Moreover, the OS benefit of
anti-angiogenesis therapy remains controversial. To ac-
quire improved better insight into the clinical benefits
of anti-angiogenesis therapy for ovarian cancer, we per-
formed a meta-analysis of the published literature on
this topic. Specifically, we assessed the prognostic value
of anti-angiogenesis therapy for the PFS and OS of ovar-
ian cancer patients.
Methods
We designed, analysed, and reported our meta-analysis
according to the PRISMA Statement guidelines.
Search strategy
A literature search (the final search was current to
Dec. 13th, 2014) of PubMed for articles addressing the
clinical benefit of anti-angiogenesis therapy in ovarian
cancer was performed using the following keywords:
(bevacizumab OR trebananib OR pazopanib OR cediranib
OR nintedanib OR imatinib OR perifosine OR sorafenib
OR sunitinib OR AEE788 OR aflibercept OR “AMG 386”
OR “BIBF 1120”) AND (“ovarian cancer” OR “ovarian
neoplasm” OR “ovarian tumor” OR “ovarian carcinoma”).
The results were limited to peer-reviewed, English language
reports. Abstracts from ASCO, ESMO and ESGO were also
screened to identify the potentially relevant studies. Add-
itionally, the references lists of the retrieved articles were
examined for potentially eligible studies.
Eligibility criteria
The studies were deemed eligible for inclusion in the
meta-analysis based on the following criteria: (i) either
the PFS or the OS benefit of anti-angiogenesis therapy
in ovarian cancer patients was reported or could be ex-
trapolated from reported data, and (ii) only randomized
clinical trials were included. Additionally, we scrutinized
all of included articles to avoid the potential influence of
redundant studies.
Data extraction
The data extracted for this meta-analysis included the
first author, anti-angiogenic agents, journal, phase, year,
treatment settings, and hazard ratios (HRs) for the PFS
and OS.
Statistical analysis
Briefly, the HRs and their respective 95 % CI were used
to assess the prognostic effect of anti-angiogenesis
therapy for ovarian cancer patients. The pooled HRs
for the PFS and OS were evaluated with fixed or
random-effects models. The potential heterogeneity be-
tween studies was estimated using the Cochran’s Q-test
and the I2 index. A fixed-effects model was used employed
when the I2 ≤ 50 %; otherwise, a random-effects model was
used. Publication bias was assessed with Egger’s and Begg’s
test. Additionally, one-way sensitivity analyses were per-
formed to evaluate the effects of the individual studies by
estimating the average HRs in the absence of each study.
All analyses were performed with STATA 11.0 software.
Results
Identification and characteristics of relevant studies
We screened 485 potentially relevant articles in our
systematic literature search and identified 10 eligible
studies (Fig. 1). Two additional reports presented at
the 2013 ESMO meeting and the 2013 ESGO biennial
meeting were also included in our meta-analysis
(Fig. 1). The characteristics of the included studies are
shown in Table 1 [8–19].
The effects of anti-angiogenesis therapy on PFS and OS
The PFS HRs were available in 11 studies. The esti-
mated pooled HR revealed that the incorporation of
anti-angiogenesis therapy was associated with an
improved PFS in ovarian cancer patients (HR, 0.66;
95 % CI, 0.58-0.75; P < 0.01; random effects; Fig. 2a).
The heterogeneity between the studies was significant
(P = 0.00, I2 = 76.4 %). There was no significant publi-
cation bias (PBegg = 0.30; PEgger = 0.17).
The HRs for OS were available in 10 studies. The esti-
mated pooled HR showed that anti-angiogenesis therapy
contributed to improved OS in ovarian cancer patients
(HR, 0.89; 95 % CI, 0.82-0.97; P = 0.01; fixed effects;
Fig. 2b). No significant heterogeneity was detected
among studies (P = 0.514, I2 = 0.0 %). There was no sig-
nificant publication bias (PBegg = 0.53; PEgger = 0.21).
Our results were further confirmed by one-way sensi-
tivity analysis (Fig. 3a, b).
Subgroup analyses of anti-angiogenesis in ovarian cancer
Subgroup analyses stratified by the anti-angiogenesis
agents indicated that administrations of each of the
agents were associated with improved PFS (Fig. 4a). The
prognostic value of anti-angiogenesis therapy for OS was
significant in the trebananib subgroup (HR, 0.81; 95 %
CI, 0.67-0.99; P = 0.04; fixed effects; Fig. 4b). The
bevacizumab subgroup exhibited a similar trend that did
not reach statistical significance (HR, 0.90; 95 % CI,
0.80-1.01; P = 0.08; fixed effects; Fig. 4b).
Moreover, the clinical benefit of anti-angiogenesis
therapy differed between the patients with primary
ovarian cancer and the patients with recurrent ovarian
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cancer. Specifically, improved PFS was observed in both
recurrent setting (HR, 0.58; 95 % CI, 0.50-0.67; P = 0.02;
random effects; Fig. 5a) and primary setting (HR, 0.78; 95 %
CI, 0.68-0.89; P = 0.01; random effects; Fig. 5a). However,
the prognostic value of anti-angiogenesis therapy for OS
was significant in the patients with recurrent ovarian cancer
(HR, 0.85; 95 % CI, 0.76-0.96; P = 0.01; fixed effects; Fig. 5b),
but not in the primary setting (HR, 0.94; 95 % CI, 0.83-1.07;
P = 0.35; fixed effects; Fig. 5b).
Discussion
Angiogenesis has been implicated in the pathogenesis
and progression of ovarian cancer potentially due to the
promotion of tumor growth, ascites, and metastases [5].
Therefore, therapies based on angiogenesis-specific
pathway are being extensively studied in ovarian cancer
[6, 7]. Our present meta-analysis was based on a pool of
8 phase III and 4 phase II clinical trials and thus differed
from the two existing meta-analyses, which included
only clinical trials involving bevacizumab [20, 21].
Namely, these two meta-analyses indicated that the
addition of bevacizumanb to chemotherapy led to sig-
nificant improvement in PFS and also increased the oc-
currence of adverse events including gastrointestinal
events, hypertension, proteinuria, and aterial thrombo-
embolism [20, 21]. The present meta-analysis revealed
that the incorporation of anti-angiogenesis therapy was
significantly associated with improvements in PFS and
OS of ovarian cancer patients. The pooled findings were
further confirmed by one-way sensitivity analyses. More
interestingly, the subgroup analyses revealed that the pa-
tients with recurrent ovarian cancer derived greater OS
benefit from the anti-angiogenesis agents. In contrast,
anti-angiogenesis therapy in the primary setting con-
ferred no significant OS benefit to ovarian cancer pa-
tients. These pooled results do not indicate that the
recurrence setting is ideal for the incorporation of anti-
angiogenesis into the treatment of ovarian cancer. In the
front-line setting, although the ICON7 and GOG218
trial failed to identify significant differences in the OS
benefits for patients according to whether bevacizumab
was added to the treatment across the entire populations
of those studies, the addition of bevacizumab to front
line therapy does confer an OS improvement for patients
who are at a high risk for progression [10, 11]. This find-
ing raised a question regarding patient selection that that
led to the use of individualized treatment regimens. Unfor-
tunately, there is still a paucity of reliable biomarkers to
predict the clinical benefit of anti-angiogenesis therapy [22].
This paucity inspired us to identify specific biomarker
signatures that can be used to stratify patients with
ovarian cancer according to the expected benefit of
anti-angiogenesis therapy [22, 23]. Possible serum
biomarkers including mesothelin, FLT4, AGP, and CA-125
were investigated [24]. Additionally, the utilities of adi-
posity measurements and dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) results as clin-
ical biomarkers for anti-angiogenesis therapy are also
currently under investigation [25, 26]. More recently,
miR-378 and its downstream targets, ALCAM and EHD1,
Fig. 1 Flow chart of the search strategy used for the selection of eligible studies
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Table 1 Characteristics of included studies
First author Agents Journal Phase Year Treatment
setting












Pujade-Lauraine E [8] Bevacizumab JCO III 2014 Recurrent 182 179 13.9 13 — 0.48 (0.38–0.60) 0.85 (0.66–1.08)
Aghajanian C [9] Bevacizumab JCO III 2012 Recurrent 242 242 24 24 — 0.48 (0.39–0.61) 1.03 (0.79–1.33)
Perren TJ [10] Bevacizumab NEJM III 2011 Primary 764 764 19.4 19.4 I-IV 0.87 (0.77–0.99) 0.85 (0.69–1.04)
Burger RA [11] Bevacizumab NEJM III 2011 Primary 625 623 17.4 17.4 III-IV 0.64 (0.55–0.76) 0.92 (0.73–1.15)
Monk BJ [12] Trebananib Lancet Oncology III 2014 Recurrent 458 461 10.1 10.1 — 0.66 (0.57–0.77) 0.86 (0.69–1.08)
Karlan BY [13]a Trebananib JCO II 2012 Recurrent 55 53 14.9 15.4 I-IV 0.81 (0.51–1.30) 0.60 (0.34–1.06)
Karlan BY [13]b Trebananib JCO II 2012 Recurrent 55 53 14.9 15.2 I-IV 0.75 (0.49–1.21) 0.77 (0.45–1.31)
du Bois A [14] Pazopanib JCO III 2014 Primary 468 472 24 24 II-IV 0.77 (0.64–0.91) 1.08 (0.87–1.33)
Liu JF [15] Cediranib Lancet Oncology II 2014 Recurrent 46 44 16.6 16.6 — 0.42 (0.23–0.76) —
Ledermann JA [16] Cediranib 2013 ESMO meeting III 2013 Recurrent — — — — — 0.57 (0.45–0.74) 0.70 (0.51–0.99)
Ledermann JA [17] Nintedanib JCO II 2011 Recurrent 40 43 — — I-IV 0.65 (0.41–1.02) 0.84 (0.51–1.39)
du Bois A [18] Nintedanib 2013 ESGO meeting III 2013 Primary 455 911 — — IIB-IV 0.84 (0.72–0.98) —












Fig. 2 Forest plots of the clinical benefit of anti-angiogenesis therapy in ovarian cancer. a The effects of anti-angiogenic agents on PFS; b The effects of
anti-angiogenic agents on OS
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have been proven to be potential biomarkers of the re-
sponse to anti-angiogenic therapy in ovarian cancer [27].
The challenge ahead is to validate these biomarkers and
implement their use in clinical practice with the goal of
providing improved guidance regarding the use of anti-
angiogenic agents.
Another intriguing finding of present study is that
trebananib seems to be active in the treatment of re-
current ovarian cancer. Improvements in both PFS and
OS were observed in the patients who were treated
with trebananib in the recurrent setting. Another phase
3 trial assessing the potential benefit of trebananib in
the recurrent setting is underway (TRINOVA-2;
NCT01281254). Moreover, the clinical benefit of the
addition of trebananib to front-line chemotherapy is
also currently under investigation in a phase 3 study
(TRINOVA-3; NCT01493505). Notably, the mechanism
by which trebananib blocks angiogenesis and its associated
Fig. 3 Confirmation of the stability of our results via one-way sensitivity analyses. a, b One-way sensitivity analyses confirmed the effects of
anti-angiogenesis therapy on PFS (a) and OS (b)
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Fig. 4 Subgroup analyses stratified according to anti-angiogenic agents. a The effects of anti-angiogenic agents on PFS; (b) The effects of
anti-angiogenic agents on OS
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Fig. 5 Subgroup analyses stratified according to treatment settings. a The effects of anti-angiogenesis therapy of PFS stratified according to
treatment setting; b The effects of anti-angiogenesis therapy on OS according to treatment settings
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toxicity profile are distinct from those of VEGF pathway in-
hibitors [12]. Thus, trebananib provides a non-VEGF
anti-angiogenesis option for the treatment of ovarian
cancer and raises the possibility that trebananib could
be combined with the VEGF pathway inhibitors, e.g.,
bevacizumab, in the treatment of ovarian cancer.
Certain limitations must be considered when inter-
preting the pooled findings. First, our meta-analysis pri-
marily focused on the PFS and OS. Indeed, the value of
the PFS for assessing the clinical benefit of new drugs
for ovarian cancer has been controversial. Additionally,
it is not appropriate to simplify the clinical benefits of
new drugs to improvements in OS, particularly when
the OS benefit of a drug is marginal, but the side effects
of that drug are life threatening. Thus, appropriately de-
signed and executed randomized trials that consider the
quality of life are needed [28]. Such trials should balance
the efficacy, safety, toxicity and cost. Second, significant
heterogeneity was found in our study. We deduced that
variability in definitions of end point, measurements, ex-
perimental design, sample size, patient characteristics,
and severity of the disease, may all represent a source of
heterogeneity in our meta-analysis. Publication bias is
another concern. We attempted to identify all of the
relevant studies, but unavoidably, some studies could
still be missing. As the additional high-quality clinical
trials related to anti-angiogenesis therapy that are under-
way are completed, further analyses can be performed to
validate the trends observed here.
Conclusions
The pooled results support the notion of a prognostic
value of anti-angiogenesis therapy in ovarian cancer
patients. The future challenge is to identify specific
subgroups of patients who stand to benefit most to
anti-angiogenesis therapy.
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